ARS Pharmaceuticals Presents Intranasal Epinephrine Data at 2024 ACAAI Annual Meeting
SAN DIEGO, Oct. 24, 2024 -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biotechnology firm committed to aiding patients at risk of severe allergic reactions, announced that seven of their research abstracts would be showcased on October 25 at the 2024 ACAAI Annual Scientific Meeting in Boston, Massachusetts. These presentations will delve into various aspects of intranasal epinephrine administration, such as cardiovascular safety studies, evaluations of carrying two devices simultaneously, and real-world data on administration in pediatric patients.
Richard Lowenthal, ARS Pharmaceuticals' Co-Founder, President, and CEO, expressed enthusiasm about the new data being presented. He highlighted that the studies not only show the effectiveness of nasal spray delivery of epinephrine in practical scenarios but also shed light on broader insights into how epinephrine functions within the body. This research is part of ARS's ongoing commitment to advancing treatment options for patients with severe allergies and enhancing the understanding within the allergy community regarding the performance of neffy®, their epinephrine nasal spray.
The studies to be presented cover a variety of topics. One study examines the cardiovascular safety of intramuscular and intranasal epinephrine administration. Another looks at blood pressure and pulse rate increases during acute allergic reactions without concomitant increases in epinephrine levels. One research specifically investigates the successful administration of ARS-1 (intranasal epinephrine) when provided with a two-dose carrying case. Another presentation addresses significant differences in the pharmacokinetic profiles among different epinephrine products and explores the underlying mechanisms for efficacy.
Further studies investigate the pharmacokinetics and pharmacodynamics of repeat dosing of ARS-1 compared to intramuscular injections during allergic rhinitis. There is also research on the development of ARS-1, offering insights from pharmacokinetics and pharmacodynamics to real-world data in pediatric food allergy patients. Lastly, one study assesses healthcare professionals' interest in ARS-1 as a self-administered intranasal epinephrine device.
Type I allergic reactions, including anaphylaxis, are serious and potentially fatal conditions that can occur rapidly after exposure to an allergen. Immediate treatment with epinephrine is crucial. While epinephrine auto-injectors have been effective, there are significant barriers to their use, such as fear of needles, portability issues, and device complexity. As a result, many patients delay or fail to administer the treatment in emergencies. In the U.S., approximately 40 million people experience allergic reactions from food, venom, or insect stings, but only a small fraction have an active epinephrine auto-injector prescription, and even fewer consistently carry it.
neffy® is an intranasal epinephrine product designed for emergency treatment of Type I allergic reactions, including those caused by food, medications, and insect bites, which can lead to life-threatening anaphylaxis. neffy® 2 mg is indicated for use in adult and pediatric patients who weigh 30 kg or more. It is recommended that patients have immediate access to two neffy nasal sprays at all times and administer a second dose if symptoms persist or worsen after the initial treatment.
Patients should be advised to seek emergency medical assistance following neffy administration to monitor the anaphylactic episode and provide further treatment if necessary. Certain conditions or medications may increase the risk of adverse reactions to epinephrine. Common side effects of neffy include throat irritation, nasal discomfort, and dizziness, among others.
ARS Pharmaceuticals is committed to improving the management of severe allergic reactions and enhancing patient care through innovative treatments like neffy®.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
